Abstract:The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing global pandemic has presented a health emergency of unprecedented magnitude. Recent clinical data has highlighted that coronavirus disease 2019 (COVID-19) is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis, venous thromboembolic disease, and stroke. Importantly, thrombotic complications are markers of severe COVID-19 and are associated with multiorgan failure and increased mortality. The evidence to date supports the concept that the thrombotic manifestations of severe COVID-19 are due to the ability of SARS-CoV-2 to invade endothelial cells via ACE-2 (angiotensin-converting enzyme 2), which is expressed on the endothelial cell surface. However, in patients with COVID-19 the subsequent endothelial inflammation, complement activation, thrombin generation, platelet, and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, ultimately causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in COVID-19. Given thrombotic complications are central determinants of the high mortality rate in COVID-19, strategies to prevent thrombosis are of critical importance. Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drugs, nafamostat, and dipyridamole, many of which also possess pleiotropic anti-inflammatory or antiviral effects. The growing awareness and mechanistic understanding of the prothrombotic state of COVID-19 patients are driving efforts to more stringent diagnostic screening for thrombotic complications and to the early institution of antithrombotic drugs, for both the prevention and therapy of thrombotic complications. The shifting paradigm of diagnostic and treatment strategies holds significant promise to reduce the burden of thrombotic complications and ultimately improve the prognosis for patients with COVID-19.

Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives

Thromboinflammation in COVID-19: Unraveling the interplay of coagulation and inflammation

Analysis of Coagulation Profile and Possible Mechanism of Coagulation Activation in COVID-19 Patients: A Systematic Literature Review

Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus

The Impact of COVID-19 Disease on Platelets and Coagulation

Viral Coagulopathy in Patients With COVID-19: Treatment and Care

Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment

Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines

COVID-19 and its implications for thrombosis and anticoagulation

Common Coagulopathies Associated With COVID-19 Patients

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

[COVID-19 from the Perspective of Haematology and Haemostaseology]

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?

Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic

COVID-19 Coagulopathy

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

COVID-19 Infection and ST-Elevation Myocardial Infarction: Lessons in Disease Management During a Pandemic

COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management

Anticoagulation for COVID-19 Patients: A Bird's-Eye View

COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management